Innate Immunity in Bullous Pemphigoid

大疱性类天疱疮的先天免疫

基本信息

  • 批准号:
    8261445
  • 负责人:
  • 金额:
    $ 36.63万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-05-15 至 2015-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Bullous pemphigoid (BP) is an autoimmune subepidermal blistering disease characterized by autoantibodies and an inflammatory infiltrate at the lesional site. BP autoantibodies belong to IgG and IgE isotypes and recognize two hemidesmosomal proteins, BP180 and BP230. In vitro and in vivo studies have demonstrated that anti- BP180 autoantibodies fix complement and are pathogenic. NC16A, an extracellular domain of BP180, is the primary target of pathogenic autoantibodies. Eosinophils are usually prominent, and the dermal infiltrate also contains neutrophils, mast cells and lymphocytes. However, roles of these key innate immune players remain unknown. Lack of a usable in vivo system is a major obstacle for studies of innate immune responses in BP using patient-derived autoantibodies. Our lab currently developed a humanized BP180 mouse stain (termed NC16A mice), in which the mouse BP180NC14A domain is replaced by the human BP180NC16A domain. More significantly, neonatal NC16A mice injected with anti-BP180 autoantibodies develop skin disease that mimics key immunological features of BP. The objective of this proposal is to study the role of eosinophils and mast cells in BP using our newly developed NC16A mouse model. The overall goal of this project is to increase our understanding of the innate immunity of BP and how it relates to the functions of innate immune system players in inflammation and autoimmunity. In Aim 1, we will determine whether mast cells are required for BP. Aim 2 is to study the role of eosinophils and to determine functional interaction between eosinophils and mast cells in BP. In Aim 3, we will study the role of proteolytic enzymes of eosinophils and mast cells in BP blistering. Since this proposal integrates both disease mechanism studies and preclinical trials, the findings are expected to have a significant impact on the treatment of patients with BP. PUBLIC HEALTH RELEVANCE: Bullous pemphigoid (BP) is the most common and potentially fatal autoimmune blistering disease. We will study the process of the disease development and identify new targets for more effective therapies.
描述(由申请人提供):大疱性类天疱疮(BP)是一种自身免疫性表皮下起泡性疾病,以自身抗体和病变部位的炎症浸润为特征。BP自身抗体属于IgG和IgE同型,识别两种半染色体蛋白BP180和BP230。体外和体内研究表明,抗BP180自身抗体固定补体并具有致病性。NC16A是BP180的胞外结构域,是致病性自身抗体的主要靶点。嗜酸性粒细胞通常突出,真皮浸润也含有中性粒细胞、肥大细胞和淋巴细胞。然而,这些关键的先天免疫参与者的作用仍然未知。缺乏可用的体内系统是使用患者来源的自身抗体研究BP先天免疫反应的主要障碍。我们的实验室目前开发了一种人源化BP180小鼠染色(称为NC16A小鼠),其中小鼠BP180NC14A结构域被人类BP180NC16A结构域取代。更重要的是,注射抗bp180自身抗体的新生NC16A小鼠会出现类似BP关键免疫学特征的皮肤病。本研究的目的是利用我们新开发的NC16A小鼠模型研究嗜酸性粒细胞和肥大细胞在BP中的作用。该项目的总体目标是增加我们对BP先天免疫的理解,以及它与炎症和自身免疫中先天免疫系统参与者的功能的关系。在目的1中,我们将确定BP是否需要肥大细胞。目的2是研究嗜酸性粒细胞的作用,并确定嗜酸性粒细胞和肥大细胞在BP中的功能相互作用。在Aim 3中,我们将研究嗜酸性粒细胞和肥大细胞的蛋白水解酶在BP起泡中的作用。由于本提案将疾病机制研究和临床前试验相结合,研究结果有望对BP患者的治疗产生重大影响。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Zhi Liu其他文献

Zhi Liu的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Zhi Liu', 18)}}的其他基金

Development of a salt-based nanomedicine for non-muscle invasive bladder cancer
开发用于非肌肉浸润性膀胱癌的盐基纳米药物
  • 批准号:
    10482565
  • 财政年份:
    2022
  • 资助金额:
    $ 36.63万
  • 项目类别:
Development of a radiation-activatable nanoparticle for lung cancer therapy
开发用于肺癌治疗的辐射激活纳米颗粒
  • 批准号:
    10259278
  • 财政年份:
    2021
  • 资助金额:
    $ 36.63万
  • 项目类别:
Inflammasome-gasdermin axis in bullous pemphigoid
大疱性类天疱疮的炎症小体-gasdermin轴
  • 批准号:
    10382402
  • 财政年份:
    2018
  • 资助金额:
    $ 36.63万
  • 项目类别:
Inflammasome-gasdermin axis in bullous pemphigoid
大疱性类天疱疮的炎症小体-gasdermin轴
  • 批准号:
    9899921
  • 财政年份:
    2018
  • 资助金额:
    $ 36.63万
  • 项目类别:
Eosinophils in Bullous Pemphigoid
大疱性类天疱疮中的嗜酸性粒细胞
  • 批准号:
    10198769
  • 财政年份:
    2017
  • 资助金额:
    $ 36.63万
  • 项目类别:
Innate Immunity in Bullous Pemphigoid
大疱性类天疱疮的先天免疫
  • 批准号:
    8073124
  • 财政年份:
    2010
  • 资助金额:
    $ 36.63万
  • 项目类别:
Innate Immunity in Bullous Pemphigoid
大疱性类天疱疮的先天免疫
  • 批准号:
    7987670
  • 财政年份:
    2010
  • 资助金额:
    $ 36.63万
  • 项目类别:
Innate Immunity in Bullous Pemphigoid
大疱性类天疱疮的先天免疫
  • 批准号:
    8461644
  • 财政年份:
    2010
  • 资助金额:
    $ 36.63万
  • 项目类别:
The Mechanism of IVIG Action in Pemphigus
IVIG 对天疱疮的作用机制
  • 批准号:
    6890262
  • 财政年份:
    2004
  • 资助金额:
    $ 36.63万
  • 项目类别:
The Mechanism of IVIG Action in Pemphigus
IVIG 对天疱疮的作用机制
  • 批准号:
    6811119
  • 财政年份:
    2004
  • 资助金额:
    $ 36.63万
  • 项目类别:

相似海外基金

Defining the cellular origin of pathogenic autoantibodies
定义致病性自身抗体的细胞起源
  • 批准号:
    EP/Y031091/1
  • 财政年份:
    2024
  • 资助金额:
    $ 36.63万
  • 项目类别:
    Fellowship
Do autoantibodies to aberrantly glycosylated MUC1 drive extra-articular rheumatoid arthritis, and can GSK assets prevent driver antigen formation?
针对异常糖基化 MUC1 的自身抗体是否会导致关节外类风湿性关节炎,GSK 资产能否阻止驱动抗原形成?
  • 批准号:
    MR/Y022947/1
  • 财政年份:
    2024
  • 资助金额:
    $ 36.63万
  • 项目类别:
    Research Grant
Autoantibodies and antibody-secreting cells in neurological autoimmune diseases: from biology to therapy
神经性自身免疫性疾病中的自身抗体和抗体分泌细胞:从生物学到治疗
  • 批准号:
    479128
  • 财政年份:
    2023
  • 资助金额:
    $ 36.63万
  • 项目类别:
    Operating Grants
Autoantibodies to tumor-derived neoepitopes as biomarkers and immunoPET agents for the early detection of small cell lung cancer
肿瘤衍生新表位的自身抗体作为生物标志物和免疫 PET 试剂用于小细胞肺癌的早期检测
  • 批准号:
    10715807
  • 财政年份:
    2023
  • 资助金额:
    $ 36.63万
  • 项目类别:
Role of pharmacological activity of autoantibodies in ME/CFS
自身抗体药理活性在 ME/CFS 中的作用
  • 批准号:
    MR/Y003667/1
  • 财政年份:
    2023
  • 资助金额:
    $ 36.63万
  • 项目类别:
    Research Grant
Pathological Mechanisms of Immune-Mediated Cerebellar Ataxia with Associated Sez6L2 Autoantibodies
免疫介导的小脑共济失调与相关 Sez6L2 自身抗体的病理机制
  • 批准号:
    10740682
  • 财政年份:
    2023
  • 资助金额:
    $ 36.63万
  • 项目类别:
Sjogren's Syndrome Pathogenic Autoantibodies
干燥综合征致病性自身抗体
  • 批准号:
    10854472
  • 财政年份:
    2023
  • 资助金额:
    $ 36.63万
  • 项目类别:
Pathogenesis of idiopathic nephrotic syndrome: defining the role of B cells and autoantibodies reactive to podocyte proteins
特发性肾病综合征的发病机制:定义 B 细胞和足细胞蛋白反应性自身抗体的作用
  • 批准号:
    487849
  • 财政年份:
    2023
  • 资助金额:
    $ 36.63万
  • 项目类别:
    Operating Grants
Depleting autoantibodies for the treatment of autoimmunity
消耗自身抗体来治疗自身免疫
  • 批准号:
    10481071
  • 财政年份:
    2022
  • 资助金额:
    $ 36.63万
  • 项目类别:
Pathological Mechanisms of Immune-Mediated Cerebellar Ataxia with Associated Sez6L2 Autoantibodies
免疫介导的小脑共济失调与相关 Sez6L2 自身抗体的病理机制
  • 批准号:
    10526475
  • 财政年份:
    2022
  • 资助金额:
    $ 36.63万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了